IP Verse

Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy

Patent No. EP2806900 (titled "Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy") was filed by Biomarin on Jan 28, 2013. The application was issued on Dec 15, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JAMES POOLESep 15, 2022CARPMAELS & RANSFORD
STRAWMANSep 15, 2022MEWBURN ELLIS

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2806900

BIOMARIN
Application Number
EP13704832A
Filing Date
Jan 28, 2013
Status
Revoked
Nov 1, 2024
Publication Date
Dec 15, 2021
External Links
Slate, Register , Google Patents